Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: BMS-986345 Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

NCT02494258
View directory record Official record
Conditions
Hematologic Neoplasm, Neoplasms, Hematologic Malignancies
Interventions
CC-486
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Gainesville, Florida • Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 13, 2026, 2:13 AM EST
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

NCT05469737
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Oral Azacitidine, Placebo for Oral Azacitidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Miami, Florida • Tamarac, Florida • East Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 13, 2026, 2:13 AM EST
Completed Phase 1 Interventional

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

NCT05065866
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma, Lymphocytic Leukemia
Interventions
BMS-986345, Duvelisib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Nov 13, 2026, 2:13 AM EST
Active, not recruiting Phase 2 Interventional Results available

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

NCT05197426
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Oral Azacitidine, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Nov 13, 2026, 2:13 AM EST